62.1 Major Depressive Disorder & Generalized Anxiety Disorder

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

62.1 Major Depressive Disorder & Generalized Anxiety Disorder

Key Takeaways Explain This Topic AI

Major Depressive Disorder (MDD) diagnosis requires at least 5 of 9 SIGECAPS symptoms present for at least 2 consecutive weeks representing a change from baseline functioning, with at least one core symptom being depressed mood or anhedonia.

Clinical screening utilizes the two-tier PHQ-2 and PHQ-9 paradigm; a PHQ-2 score of 3 or higher mandates reflex PHQ-9 testing, where any endorsement of item 9 (suicidal ideation) requires immediate, direct suicide risk stratification and safety planning.

Antidepressant management progresses through three distinct phases: acute phase (6-12 weeks to achieve full remission, PHQ-9 < 5), continuation phase (4-9 months at full therapeutic dose to prevent relapse), and maintenance phase (1-3 years or indefinitely for patients with 3 or more recurrent episodes, chronic depression 2 years or longer, or severe suicide attempts).

Bupropion provides an activating alternative with zero sexual dysfunction and weight neutrality but is strictly contraindicated in patients with seizure disorders, anorexia nervosa, or bulimia nervosa due to lowered seizure threshold; mirtazapine is ideal for depression with insomnia and cachexia via potent H1 antagonism.

Generalized Anxiety Disorder requires excessive, uncontrollable worry for at least 6 months about diverse events with 3 or more somatic/cognitive symptoms; cognitive behavioral therapy (CBT) and SSRIs/SNRIs are first-line, while benzodiazepines must be strictly limited to acute short-term crisis stabilization (2-4 weeks or less) to prevent tolerance, dependence, cognitive blunting, and fall risk.

Last updated: September 2026

Epidemiology & Neurobiology of Mood and Anxiety Disorders

Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD) represent two of the most prevalent and disabling conditions encountered in ambulatory family medicine. In the United States, MDD carries a lifetime prevalence exceeding 20%, with women affected roughly twice as often as men. GAD has a lifetime prevalence of approximately 6% to 8%. Comorbidity is the rule rather than the exception: over 55% to 60% of patients with major depression meet diagnostic criteria for a coexisting anxiety disorder, and comorbid anxiety significantly increases chronicity, suicide risk, functional disability, and treatment resistance. CORTICO-LIMBIC DYSREGULATION IN DEPRESSION & ANXIETY

• Chronic Psychological Stress / Genetic Diathesis / Environmental Adversity
• │
• ▼
• Hypothalamic-Pituitary-Adrenal (HPA) Axis Hyperactivity
• Impaired glucocorticoid receptor feedback
• Sustained circulating hypercortisolemia
• │
• ┌──────────────────────────────┴──────────────────────────────┐
• ▼ ▼
• Hippocampal & Prefrontal Pathology Amygdala Hyperactivity
• Decreased Brain-Derived Neurotrophic • Loss of top-down inhibitory gating
• Factor (BDNF) expression • Heightened threat reactivity
• Dendritic atrophy & synaptic pruning • Autonomic hyperarousal & worry
• Impaired cognitive flexibility & executive function
• │
• ▼
• Monoaminergic Deficits & Cortico-Striatal Network Uncoupling
• Serotonin (5-HT): Dysphoria, anxiety, panic, rumination, suicidality
• Norepinephrine (NE): Fatigue, apathy, psychomotor blunting, autonomic instability
• Dopamine (DA): Anhedonia, loss of motivation, impaired reward salience

The pathophysiological underpinnings of MDD and GAD extend far beyond simplistic "chemical imbalance" theories. Current neurobiological models emphasize maladaptive neuroplasticity, sustained neuroinflammation, and network-level dysregulation within the cortico-limbic circuit. Chronic hyperactivation of the hypothalamic-pituitary-adrenal (HPA) axis results in sustained hypercortisolemia, which impairs glucocorticoid receptor sensitivity and downregulates brain-derived neurotrophic factor (BDNF). This drives dendritic arborization loss and synaptic atrophy within the hippocampus and dorsolateral prefrontal cortex (DLPFC). Concurrently, loss of top-down prefrontal inhibitory control allows unchecked hyperactivity of the amygdala, generating pathological apprehension, hypervigilance, autonomic arousal, and somatic anxiety.

Diagnostic Criteria for Major Depressive Disorder (MDD)

Under DSM-5-TR, a definitive diagnosis of a Major Depressive Episode requires the presence of at least 5 of the following 9 symptoms during the same 2-week period , representing a clear change from previous baseline functioning. Crucially, at least one of the symptoms MUST be either (1) Depressed mood or (2) Loss of interest or pleasure (anhedonia) . DSM-5 DIAGNOSTIC CRITERIA: SIGECAPS

• Mnemonic Symptom Domain Diagnostic Specification & Clinical Manifestation
• ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
• [S] Sleep Insomnia or Hypersomnia Terminal early morning awakening (waking 2-3 hours
• before alarm, unable to sleep) is classic; middle insomnia

or hypersomnia (>10-12 hours/day) also qualify.

• ─────────────────────────────────────────────────────────────────────────────────────────────────────────
• [I] Interest Anhedonia (CORE SYMPTOM) Markedly diminished interest or pleasure in all, or almost

all, activities most of the day, nearly every day.

• ─────────────────────────────────────────────────────────────────────────────────────────────────────────
• [G] Guilt Worthlessness or Guilt Excessive, inappropriate, or delusional guilt; intense

self-reproach beyond ordinary regret or low self-esteem.

• ─────────────────────────────────────────────────────────────────────────────────────────────────────────
• [E] Energy Fatigue or Loss of Energy Subjective exhaustion without physical exertion; basic

hygiene and self-care tasks require monumental effort.

• ─────────────────────────────────────────────────────────────────────────────────────────────────────────
• [C] Concentr. Impaired Cognitive Function Diminished ability to think, sustain attention, or make

decisions; executive dysfunction; indecisiveness.

• ─────────────────────────────────────────────────────────────────────────────────────────────────────────
• [A] Appetite Weight or Appetite Changes Involuntary weight loss or gain of >= 5% body weight

within a single month; severe anorexia or hyperphagia.

• ─────────────────────────────────────────────────────────────────────────────────────────────────────────
• [P] Psychom. Agitation or Retardation Observable by others (not merely subjective feelings);

pacing, hand-wringing, or slowed speech and body movements.

• ─────────────────────────────────────────────────────────────────────────────────────────────────────────
• [S] Suicide Suicidal Ideation / Thoughts Recurrent thoughts of death, recurrent suicidal ideation

with or without a specific plan, or a suicide attempt.

• ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
• Mandatory Clinical Exclusions

Before confirming unipolar MDD, the clinician must systematically exclude alternative medical, substance-induced, or psychiatric etiologies:

Substance or Medication Induction : Rule out alcohol misuse, stimulant withdrawal, benzodiazepine dependence, prescription corticosteroids, beta-blockers, interferon-alpha, or varenicline.

Underlying Medical Conditions : Screen for severe hypothyroidism (elevated TSH), hyperparathyroidism (hypercalcemia), Cushing syndrome, systemic lupus erythematosus, pancreatic adenocarcinoma, vitamin B12 deficiency, or recent cerebrovascular accident.

Bipolar Disorder : Verify that the patient has NEVER experienced a manic or hypomanic episode . The presence of even a single prior manic episode permanently establishes Bipolar I Disorder, for which unipolar antidepressant monotherapy is strictly contraindicated.

Screening Protocols & Suicide Risk Assessment

The United States Preventive Services Task Force (USPSTF) recommends universal screening for depression in the general adult population, including pregnant and postpartum individuals. A two-tier screening strategy balances clinical efficiency with high diagnostic accuracy. TWO-TIER DEPRESSION SCREENING ALGORITHM

• Administer Patient Health Questionnaire-2 (PHQ-2)
• Over past 2 weeks: Depressed mood? (0-3)
• Over past 2 weeks: Anhedonia? (0-3)
• │
• ┌───────────────┴───────────────┐
• ▼ ▼
• Score 0 to 2 Score >= 3
• (Screen Negative) (Screen Positive)
• │ │
• ▼ ▼
• Rescreen Annually or Mandatory Reflex Administration
• with Clinical Changes of Full 9-Item PHQ-9
• PHQ-9 Scoring Stratification & Action Plan

0 to 4 (Minimal/None) : No intervention required; lifestyle encouragement.

5 to 9 (Mild) : Watchful waiting, sleep hygiene, aerobic exercise, re-evaluation in 4 to 8 weeks; consider low-intensity psychotherapy if functional impairment is present.

10 to 14 (Moderate) : First-line pharmacotherapy (SSRI or SNRI) OR evidence-based psychotherapy (Cognitive Behavioral Therapy [CBT] or Interpersonal Therapy [IPT]). Combination therapy preferred if chronic.

15 to 19 (Moderately Severe) : Pharmacotherapy combined with manualized psychotherapy.

20 to 27 (Severe) : Immediate pharmacotherapy, intensive psychotherapy, safety assessment, and consideration of psychiatric referral or electroconvulsive therapy (ECT) evaluation.

Critical Protocol for Item 9 (Suicidal Ideation)

Item 9 of the PHQ-9 assesses whether the patient has experienced "thoughts that you would be better off dead, or of hurting yourself in some way." Any score >= 1 on Item 9 mandates immediate, direct, in-person clinical suicide risk stratification :

Stratification Questions : Assess active vs. passive ideation, presence of a specific plan, rehearsal or preparatory behaviors, intent to act, and immediate access to lethal means (specifically inquiring about firearms and stockpiled medications in the home).

Standardized Tool : The Columbia-Suicide Severity Rating Scale (C-SSRS) should be documented in the electronic medical record.

Lethal Means Counseling : The single most effective environmental suicide prevention intervention is removing firearms and lethal prescription drugs from the patient's immediate possession.

Safety Planning : Construct a written Stanley-Brown Safety Plan identifying internal coping strategies, distracting social contacts, trusted family members, and 24/7 emergency hotlines (dialing or texting 988 in the US).

Emergency Disposition : If the patient demonstrates active intent, a high-lethality plan, and lack of impulse control or refusal to engage in safety planning, emergency voluntary or involuntary psychiatric evaluation is legally and ethically required. Do not leave the patient unattended.

The Three Phases of Depression Management

Successful management of MDD requires understanding that therapeutic intervention extends far beyond initial symptom reduction. Treatment is divided into three distinct phases: THE THREE PHASES OF MDD TREATMENT

• Index Major Response Full Remission
• Depressive (>=50% PHQ-9 (PHQ-9 < 5)
• Episode reduction) │
• │ │ │
• ▼ ▼ ▼
• ┌───────────────────────────────────┬────────────────┬──────────────────────────┐
• │ ACUTE PHASE │ CONTINUATION │ MAINTENANCE PHASE │
• │ (6-12 Weeks) │ PHASE │ (1-3 Years or Life) │
• │ │ (4-9 Months) │ │
• │ • Goal: Achieve full remission │ • Goal: Prevent│ • Goal: Prevent │
• │ • Titrate to full therapeutic dose│ RELAPSE │ RECURRENCE │
• │ • Assess response at 4-6 weeks │ • Maintain full│ • Indicated for >=3 prior│
• │ • Change/augment if <25% response │ remission │ episodes, chronic >=2y,│
• │ │ dose │ or severe suicidality │
• └───────────────────────────────────┴────────────────┴──────────────────────────┘

Acute Phase (6 to 12 Weeks) :

Primary Objective : Achieve complete clinical remission , defined as virtually complete resolution of depressive symptoms (PHQ-9 score < 5) and full restoration of psychosocial functioning.

Clinical Pitfall : Settling for "response" (defined as a >=50% reduction in baseline PHQ-9 score, e.g., dropping from 20 to 10). Patients with residual depressive symptoms have a 3- to 6-fold higher rate of early relapse, chronic functional impairment, and elevated suicide risk.

Timeline : An adequate medication trial requires 6 to 8 weeks at the maximum tolerated therapeutic dose . If no improvement (<20% to 25% reduction in PHQ-9) is observed after 4 to 6 weeks at a therapeutic dose, adherence must be verified, followed by dose escalation or switching to another first-line agent.

Continuation Phase (4 to 9 Months Post-Remission) :

Primary Objective : Prevent relapse , which represents the return of the original index depressive episode before full neurobiological recovery.

Cardinal Rule : The antidepressant must be maintained at the exact same full therapeutic dose that induced remission . Tapering or reducing the dose during this vulnerable 4-to-9-month window dramatically spikes relapse rates to over 50%.

Maintenance Phase (1 to 3 Years or Indefinitely) :

Primary Objective : Prevent recurrence , which represents the development of a brand new, separate depressive episode.

Evidence-Based Indications for Long-Term/Indefinite Maintenance :

History of 3 or more lifetime major depressive episodes .

Severe chronic depression (symptoms persisting continuously for >= 2 years).

History of severe, high-lethality suicide attempts or psychotic features.

Residual depressive symptoms or high underlying psychiatric/medical comorbidity.

First-Line Pharmacotherapy: SSRIs and SNRIs

Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) represent the primary first-line pharmacotherapeutic options for both MDD and GAD due to their proven efficacy, favorable tolerability, and safety in overdose compared to first-generation tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs). FIRST-LINE SSRI & SNRI PHARMACOTHERAPY

• Medication Initial Dose Target Dose Mechanism & Key Pearls Adverse Effects & Risks
• ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
• Sertraline 25-50 mg daily 100-200 mg daily Preferred in cardiovascular Transient GI distress,
• (Zoloft) disease (SADHART trial safe diarrhea, sexual dysfunction

post-MI); mild DAT uptake. (30-50%), headache.

• ─────────────────────────────────────────────────────────────────────────────────────────────────────────
• Escitalopram 10 mg daily 10-20 mg daily Pure S-enantiomer; highest Dose-dependent QTc
• (Lexapro) selectivity for 5-HT; lowest prolongation: max dose 10 mg

CYP450 drug interactions. daily in elderly (>=60 years).

• ─────────────────────────────────────────────────────────────────────────────────────────────────────────
• Fluoxetine 10-20 mg daily 20-60 mg daily Longest half-life (nor- Activating (insomnia, jitteriness);
• (Prozac) fluoxetine t1/2 = 7-15 days); potent CYP2D6 inhibitor; 5-week

self-tapering; misses fine. washout required before MAOIs.

• ─────────────────────────────────────────────────────────────────────────────────────────────────────────
• Duloxetine 30 mg daily for 60 mg daily Dual 5-HT and NE reuptake Nausea, constipation, dry mouth;
• (Cymbalta) 1 week, then 60 (max 120 mg/day) inhibition; FDA-approved for contraindicated if eGFR < 30

neuropathic pain & fibro. mL/min or hepatic impairment.

• ─────────────────────────────────────────────────────────────────────────────────────────────────────────
• Venlafaxine ER 37.5-75 mg daily 150-225 mg daily Acts as SSRI at <150 mg; Dose-dependent diastolic
• (Effexor XR) (max 375 mg/day) robust NE block at >=150 mg; hypertension; severe withdrawal

potent, rapid response. syndrome upon missed doses.

• ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
• SSRI/SNRI Class Adverse Effects & Clinical Management

Gastrointestinal Distress : Nausea, loose stools, and abdominal cramping occur in 15% to 25% of patients due to peripheral stimulation of 5-HT3 and 5-HT4 receptors in the enteric nervous system. These symptoms are self-limited and typically resolve within 7 to 14 days. Taking the medication with meals or starting at half-doses mitigates nausea.

Sexual Dysfunction : Affects 30% to 50% of patients on SSRIs/SNRIs, presenting as delayed ejaculation, anorgasmia, erectile dysfunction, and diminished libido. Crucially, SSRI-induced sexual dysfunction rarely develops tolerance and does not resolve spontaneously . Management involves switching to or augmenting with bupropion, dose reduction, or phosphodiesterase-5 inhibitors.

Hyponatremia & SIADH : Syndrome of Inappropriate Antidiuretic Hormone Secretion occurs primarily in older adults (>=65 years), especially those concurrently taking thiazide diuretics or NSAIDs. Baseline and follow-up serum electrolytes should be checked within 2 to 4 weeks in elderly patients starting an SSRI.

Bleeding Diathesis : Serotonin is taken up by platelets to facilitate platelet aggregation. SSRIs deplete platelet serotonin stores, mildly increasing the risk of upper gastrointestinal bleeding. Exercise caution and consider gastroprotective proton pump inhibitors when co-prescribing with NSAIDs, aspirin, or systemic anticoagulants.

FDA Black Box Warning for Pediatric and Young Adult Suicidality : In 2004, the FDA issued a black box warning stating that antidepressants increase the risk of suicidal thoughts and behaviors in children, adolescents, and young adults aged 24 years or younger during the initial weeks of treatment. Landmark meta-analyses demonstrate that while suicidal ideation reports increase slightly (approximately 4% on drug vs. 2% on placebo), completed suicides do not increase . The absolute benefit of treating depression significantly outweighs the risk, but close weekly or biweekly monitoring is mandatory during the initial 4 to 8 weeks.

Atypical Antidepressants: Bupropion & Mirtazapine

Atypical antidepressants provide highly strategic therapeutic alternatives when first-line SSRIs/SNRIs fail, produce intolerable side effects, or when specific clinical comorbidities dictate tailored pharmacotherapy. ATYPICAL ANTIDEPRESSANT PHARMACOLOGY

Medication Pharmacodynamic Mechanism Clinical Indications & Benefits Contraindications & Adverse Risks

═══════════════════════════════════════════════════════════════════════════════════════════════════════════════

• Bupropion Norepinephrine-Dopamine • Depression with severe fatigue, • STRICT CONTRAINDICATION in
• (Wellbutrin Reuptake Inhibitor (NDRI). apathy, or psychomotor blunting. seizure disorders, active or

SR / XL) Blocks DAT and NET; no direct • Zero sexual dysfunction. prior anorexia or bulimia.

serotonergic activity. • Weight neutral / weight loss. • Contraindicated with abrupt

• Comorbid ADHD / smoking (Zyban). alcohol or benzo cessation.

───────────────────────────────────────────────────────────────────────────────────────────────────────────

Mirtazapine Central presynaptic alpha-2 • Depression with severe insomnia • Marked weight gain / hyperphagia.

• (Remeron) antagonist; blocks postsynaptic and anorexia / cachexia. • Sedation (paradoxically more
• 5-HT2 and 5-HT3 receptors; • Excellent in frail elderly. sedating at 7.5-15 mg than

potent H1 histamine antagonist. • Minimal sexual dysfunction. at higher doses of 30-45 mg).

═══════════════════════════════════════════════════════════════════════════════════════════════════════════════

Bupropion: Clinical Pearls & Strict Contraindications

Bupropion is an activating, non-serotonergic agent that elevates synaptic dopamine and norepinephrine. It is an outstanding choice for patients suffering from lethargy, hypersomnia, cognitive sluggishness, or nicotine dependence. It is the only first-line antidepressant that does not cause sexual dysfunction and frequently induces mild weight loss.

Absolute Contraindications (ABFM Board Essentials) :

History of Seizure Disorder : Bupropion dose-dependently lowers the seizure threshold (incidence of seizures is ~0.1% at <=300 mg/day of XL, but rises sharply at higher doses).

Active or Prior Diagnosis of Anorexia Nervosa or Bulimia Nervosa : Patients with active or prior purging behaviors and electrolyte disturbances experience an unacceptable, 4- to 10-fold higher incidence of grand mal seizures when exposed to bupropion.

Abrupt Withdrawal from Alcohol, Benzodiazepines, or Barbiturates : Sudden cessation of GABA-enhancing agents drastically lowers seizure threshold and combined with bupropion triggers status epilepticus.

Concurrent MAOI Use : Requires a mandatory 14-day washout period.

Mirtazapine: The Inverse Sedation Profile & Geriatric Pearl

Mirtazapine uniquely enhances noradrenergic and serotonergic release through presynaptic alpha-2 auto- and hetero-receptor antagonism while blocking 5-HT2, 5-HT3, and histamine H1 receptors. Its potent antihistaminic action drives deep sleep consolidation and prominent appetite stimulation with weight gain.

The Dosing Paradox : At low doses ( 7.5 to 15 mg at bedtime ), H1 antihistaminic affinity heavily predominates, inducing profound sedation and cravings for carbohydrates. At higher doses ( 30 to 45 mg at bedtime ), increased central noradrenergic transmission overrides the antihistaminic sedation, resulting in a more alerting profile. Clinicians should educate patients that increasing the dose to 30 mg often diminishes morning grogginess.

Geriatric Application : Mirtazapine is the premier agent for frail older adults residing in nursing homes who present with depression, severe sleep fragmentation, and progressive involuntary weight loss (failure to thrive).

Augmentation Strategies for Treatment-Resistant Depression

When a patient fails to achieve full remission despite an adequate trial of a first-line antidepressant at maximum tolerated doses, the clinician must determine whether to switch agents or augment the current regimen. If the patient has achieved a partial response (30% to 50% symptom reduction) with good tolerability, evidence strongly favors augmentation rather than discarding partial progress. EVIDENCE-BASED AUGMENTATION PARADIGM FOR MDD

• Partial Response to SSRI / SNRI
• (30% to 50% PHQ-9 reduction)
• │
• ┌──────────────────────────┬──────────┴──────────┬──────────────────────────┐
• ▼ ▼ ▼ ▼
• Add Bupropion Add Low-Dose Add Lithium Carbonate Add Manualized CBT
• (150-300 mg XL) Atypical Antipsychotic (0.6 - 0.8 mEq/L) (12-16 weekly sessions)
• Synergistic DAT/NET block • Aripiprazole 2-5 mg • Proven antisuicidal • Equivalent efficacy
• Reverses sexual dysfxn • Brexpiprazole 0.5-2mg efficacy in unipolar to drug augmentation
• Activating / improves • Quetiapine 150-300mg refractory depression • Sustained relapse
• energy and concentration • Rapid onset (1-2 wks) • Monitor renal/thyroid prevention

Bupropion Augmentation : Adding bupropion XL 150 to 300 mg daily to an SSRI provides dual-transmitter synergy (5-HT + NE + DA), mitigates SSRI-induced sexual side effects, and treats residual apathy and fatigue.

Second-Generation Antipsychotic (SGA) Augmentation : Low-dose Aripiprazole (2 to 5 mg daily) is FDA-approved and highly effective for unipolar depression augmentation. As a dopamine D2 partial agonist, it enhances prefrontal dopamine signaling without inducing significant sedation or metabolic syndrome. Brexpiprazole and extended-release Quetiapine (150 to 300 mg daily) are alternative options.

Lithium Augmentation : Adding lithium carbonate (titrated to a serum trough level of 0.6 to 0.8 mEq/L ) has robust randomized trial support, converting roughly 50% of antidepressant non-responders to responders and uniquely conferring anti-suicide protection.

Generalized Anxiety Disorder (GAD): Diagnosis & Management

Under DSM-5-TR, Generalized Anxiety Disorder is characterized by excessive, uncontrollable anxiety and worry (apprehensive expectation) occurring more days than not for at least 6 months , about a wide variety of everyday events, activities, or domains (e.g., finances, work, health of family members, minor responsibilities). DSM-5 DIAGNOSTIC CRITERIA FOR GAD

• Excessive, uncontrollable worry occurring more days than not for >= 6 months
• PLUS
• At least 3 of the following 6 somatic/cognitive symptoms

(Only 1 symptom required in pediatric patients):

• 1. Restlessness or feeling keyed up, on edge, or unable to relax
• 2. Being easily fatigued or exhausted by minor mental effort
• 3. Difficulty concentrating or mind going completely blank
• 4. Irritability or low frustration tolerance
• 5. Muscle tension (cervical/trapezius tightness, jaw clenching, trembling)
• 6. Sleep disturbance (difficulty falling or staying asleep; restless, unrefreshing sleep)
• Clinical Assessment & GAD-7 Scale

The Generalized Anxiety Disorder 7-item scale (GAD-7) is the validated screening and monitoring instrument. Scores of 5, 10, and 15 represent validated cut-offs for mild, moderate, and severe anxiety, respectively. A score >= 10 demonstrates 89% sensitivity and 82% specificity for GAD, warranting active therapeutic intervention.

Comprehensive Management Strategy

Cognitive Behavioral Therapy (CBT) : Gold-standard first-line non-pharmacologic psychotherapy. Focuses on identifying cognitive distortions (catastrophizing, probability overestimation), exposure to uncertainty, and somatic relaxation training. Effect sizes match or exceed pharmacotherapy, with significantly greater durability after therapy termination.

First-Line Pharmacotherapy : SSRIs (Escitalopram, Sertraline, Paroxetine) and SNRIs (Duloxetine, Venlafaxine ER) are first-line. Dosing Rule : Always initiate at half the standard starting dose used in depression (e.g., escitalopram 5 mg daily or sertraline 25 mg daily) because anxiety patients are exquisitely sensitive to transient, early serotonergic agitation. Titrate slowly over 4 to 8 weeks.

Buspirone : A high-affinity 5-HT1A receptor partial agonist. It exerts anxiolytic effects without causing sedation, psychomotor slowing, cognitive blunting, or respiratory depression. Zero potential for abuse, dependence, or tolerance (non-scheduled agent). Does not cause sexual dysfunction or weight gain.

Clinical Administration : Must be dosed regularly on a scheduled basis (start 7.5 mg BID, titrate to 15-30 mg BID) . It has NO utility as a PRN rescue medication because clinical onset requires 2 to 4 weeks of continuous daily administration. It is less effective in patients with extensive prior benzodiazepine exposure who expect immediate sedation.

Benzodiazepine Stewardship & Deprescribing Protocols

While benzodiazepines (e.g., lorazepam, clonazepam, alprazolam) offer immediate GABA-A mediated anxiolysis, their role in modern family medicine is strictly restricted to short-term crisis stabilization (<=2 to 4 weeks) as a bridging agent while awaiting the onset of SSRI/SNRI efficacy.

Dangers of Chronic Benzodiazepines : Rapid emergence of pharmacodynamic tolerance, severe physical dependence, rebound anxiety, cognitive decline, emotional blunting, and heightened risk of motor vehicle collisions.

Geriatric Beers Criteria : Benzodiazepines are strongly contraindicated in older adults (>=65 years) due to dramatic increases in delirium, ataxia, falls, and fatal hip fractures.

Deprescribing Protocol : For patients on long-term benzodiazepines, never discontinue abruptly due to risks of life-threatening withdrawal seizures, delirium tremens, and cardiovascular collapse. Convert short-acting agents to long-acting diazepam or clonazepam, and execute a slow outpatient taper: reduce the total daily dose by 10% to 25% every 1 to 2 weeks over 2 to 6 months , incorporating concurrent CBT to manage rebound anxiety.

Serotonin Syndrome: Recognition & Emergency Management

Serotonin syndrome (serotonin toxicity) is an unpredictable, potentially fatal condition characterized by excessive intrasynaptic serotonin concentrations resulting from therapeutic drug combinations, intentional overdoses, or drug-drug interactions involving serotonergic agents (e.g., SSRIs, SNRIs, TCAs, MAOIs, tramadol, meperidine, fentanyl, dextromethorphan, linezolid, methylene blue, triptans, and St. John's wort). HUNTER SEROTONIN TOXICITY CRITERIA

• To establish the diagnosis, the patient MUST be taking a serotonergic agent
• AND

Demonstrate AT LEAST ONE of the following:

• 1. Spontaneous Clonus
• 2. Inducible Clonus ─── PLUS ─── Agitation OR Diaphoresis
• 3. Ocular Clonus ─── PLUS ─── Agitation OR Diaphoresis
• 4. Tremor ─── PLUS ─── Hyperreflexia

5. Hypertonia ─── PLUS ─── Temperature > 38.0°C (100.4°F) ─── PLUS ─── Ocular or Inducible Clonus SEROTONIN SYNDROME VS. NEUROLEPTIC MALIGNANT SYNDROME (NMS)

• Clinical Feature Serotonin Syndrome (Hunter) Neuroleptic Malignant Syndrome (NMS)
• ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
• Causative Agents Serotonergic drugs (SSRIs, SNRIs, Dopamine antagonists (haloperidol, fluphenazine,
• tramadol, linezolid, MAOIs) atypical antipsychotics, metoclopramide)
• ─────────────────────────────────────────────────────────────────────────────────────────────────────────
• Onset of Symptoms RAPID: develops within 6 to 24 hours INSIDIOUS: develops over days to weeks
• following drug initiation or overdose following initiation or dose escalation
• ─────────────────────────────────────────────────────────────────────────────────────────────────────────
• Neuromuscular Signs HYPERREFLEXIA, CLONUS (spontaneous or "LEAD-PIPE" RIGIDITY, HYPOREFLEXIA,
• inducible), tremor; lower > upper bradykinesia, generalized dystonia
• ─────────────────────────────────────────────────────────────────────────────────────────────────────────
• Pupils & Bowel MYDRIASIS (dilated pupils), NORMAL pupils, normal or hypoactive
• HYPERACTIVE bowel sounds, diarrhea bowel sounds
• ─────────────────────────────────────────────────────────────────────────────────────────────────────────
• Temperature & Skin Hyperthermia (>38-40°C), diaphoresis, Severe hyperthermia (>38-41°C), diaphoresis,
• erythema, shivering pallor, metabolic acidosis
• ─────────────────────────────────────────────────────────────────────────────────────────────────────────
• Specific Antidote CYPROHEPTADINE (5-HT2A antagonist) DANTROLENE (ryanodine blocker), BROMOCRIPTINE
• ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
• Emergency Management Algorithm for Serotonin Syndrome

Immediate Decontamination : Immediately discontinue all serotonergic medications.

Supportive Care : Administer high-flow supplemental oxygen, continuous cardiac telemetry, and vigorous IV crystalloid hydration (to treat rhabdomyolysis and prevent acute tubular necrosis from myoglobinuria).

Chemical Sedation with Benzodiazepines : IV Lorazepam (1 to 2 mg every 15 to 30 minutes) is the cornerstone of emergency pharmacotherapy. Benzodiazepines blunt autonomic hyperactivity, abolish muscle tremors, diminish psychomotor agitation, and reduce metabolic heat production.

Aggressive External Cooling : In patients with severe hyperthermia (>40°C / 104°F), initiate external cooling immediately with cooling blankets, ice baths, and evaporative fans. Antipyretics (acetaminophen, ibuprofen) are completely ineffective because elevated temperature is driven by peripheral muscular contractions, not hypothalamic set-point alteration.

Specific Serotonin Antagonist : Administer Cyproheptadine (a potent 5-HT2A and 5-HT1 antagonist) in moderate-to-severe cases. Administer an initial loading dose of 12 mg orally or via nasogastric tube , followed by 2 mg every 2 hours until clinical stabilization is achieved (maintenance: 8 mg every 6 hours).

Critical Care & Neuromuscular Paralysis : If hyperthermia exceeds 41.1°C (106°F) or severe muscular rigidity compromises ventilation, immediately perform endotracheal intubation and induce complete paralysis with a non-depolarizing neuromuscular blocker (e.g., vecuronium) . Never administer succinylcholine due to extreme risks of lethal hyperkalemic cardiac arrest secondary to rhabdomyolysis.

Loading diagram... Clinical Algorithm for MDD and GAD Assessment and Stepwise Pharmacotherapy